• If you are wondering whether Centene’s current share price reflects its true worth, you are not alone. This article is here to unpack what the numbers are really saying about the stock.
• Centene’s share price closed at US$43.24, with returns of 6.6% over the last 7 days, a 6.2% decline over 30 days, a 3.5% gain year to date, and longer term returns of a 25.0% decline over 1 year, a 38.5% decline over 3 years, and a 26.1% decline over 5 years.
• Recent coverage around Centene has focused on its position in managed care and government sponsored health plans, highlighting how policy developments and contract dynamics can affect investor sentiment. News flow like this often feeds into how the market prices healthcare companies that are closely tied to public programs, which can help explain some of the recent share price moves.
• On our valuation checks, Centene scores 5 out of 6 for being undervalued, giving it a valuation score of 5/6. Next, we will look at what different valuation methods suggest about the stock, and then round out with a way of thinking about valuation that can give you an even clearer picture.

Approach 1: Centene Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today’s value. It is essentially asking what Centene’s future cash generation is worth in today’s dollars.

For Centene, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash that could theoretically be available to shareholders. The latest twelve month free cash flow is reported at about US$4.25b. Analyst and extrapolated projections, provided up to 2035, point to free cash flow reaching about US$4.04b in 2030, with intermediate years stepping up via a mix of analyst estimates and calculated extensions.

When all of those projected cash flows are discounted back and added together, Simply Wall St’s DCF model arrives at an intrinsic value of about US$217.25 per share. Compared with the recent share price of US$43.24, this implies an intrinsic discount of roughly 80.1%, which indicates that the model views Centene as significantly undervalued on this cash flow basis.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Centene is undervalued by 80.1%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: Centene Price vs Sales

For companies like Centene that are heavily focused on large revenue contracts, the P/S ratio is often a useful cross check because it ties the share price directly to the revenue base rather than accounting earnings, which can be influenced by one off items and non cash charges.

In general, higher growth expectations and lower perceived risk tend to support a higher “normal” P/S multiple, while slower expected growth or higher risk are usually associated with a lower multiple. It is therefore helpful to compare Centene’s current P/S with a few benchmarks.

Centene is trading on a P/S of 0.12x. The Healthcare industry average P/S is 1.29x and the peer group average sits at 1.49x, so the stock is priced at a lower sales multiple than both of those reference points. Simply Wall St’s “Fair Ratio” for Centene is 0.78x, which is the P/S level their model suggests based on factors such as earnings growth, profit margin, industry, market cap and company specific risks.

This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for those factors instead of assuming that all companies deserve the same multiple. Comparing 0.12x to the 0.78x Fair Ratio indicates that the shares are trading below that model based estimate.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies.

Upgrade Your Decision Making: Choose your Centene Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, where you tell a clear story about Centene and link that story to your own revenue, earnings and margin estimates. These then flow into a fair value that you can compare with the current price on Simply Wall St’s Community page. Your Narrative updates automatically when new news or earnings arrive, and it can even differ sharply from other investors. For example, one Narrative currently sees Centene’s fair value at about US$26.83 and another at about US$62.81, while the analyst consensus Narrative sits closer to about US$44.18. This gives you a simple way to see how your view lines up before you decide whether the gap between price and fair value is wide enough to act on.

For Centene, however, here are previews of two leading Centene narratives to make comparison easier:

Here is how one bullish community view and one more cautious view line up on the numbers you have just seen.

Fair value: US$95.24 per share

Current pricing gap: about 54.6% below this fair value based on the recent US$43.24 share price

Revenue growth used in this narrative: 4%

• Frames Centene as a leading player in Medicaid and Affordable Care Act plans, where a sharp share price drop followed higher medical costs and the withdrawal of 2025 guidance, with the view that the market reaction may have gone too far.
• Points to potential supports such as higher ACA premiums across 29 states from 2026, improved Medicaid contract terms, and a US$2,000m share repurchase program.
• Flags key watchpoints including sustained high medical cost ratios, possible cuts to ACA or Medicaid support, and regulatory penalties, with the author treating the position as tactical around upcoming earnings.

Fair value: US$32.00 per share

Current pricing gap: about 35.1% above this fair value based on the recent US$43.24 share price

Revenue growth used in this narrative: 3.55%

• Focuses on pressure from regulation, reimbursement rates and contract uncertainty in Medicaid and Marketplace, along with shifting demographics that could keep medical cost ratios and margins under strain.
• Highlights operational challenges such as integration complexity and higher SG&A, as well as competition from new healthcare models and Centene’s reliance on government contracts.
• Uses a fair value anchored near the lower end of analyst targets at US$24.00 as a cross check, with the view that contract risk, rate decisions and policy changes could justify a lower valuation if earnings and margins do not improve as expected.

Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.